Business context and reporting period
This is the Form 10-K of Virtual Crypto Technologies, Inc. (formerly Emerald Medical Applications Corp.) for the fiscal year ended December 31, 2017. The request metadata names Quantum X Labs Inc.; that name does not match the registrant identified in the filing.
During 2017, the company pursued its DermaCompare skin-imaging business, which generated no revenue. In January 2018, it formed a new Israeli subsidiary to develop and market cryptocurrency purchase-and-sale products for ATMs and other devices, and began winding down its former subsidiary. Emerald IL ceased to be part of the company effective March 8, 2018.
Financial performance and position
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $1,266,390 | $5,394,735 |
| Operating loss | $1,266,390 | $5,394,735 |
| Net loss | $1,573,906 | $6,145,197 (restated) |
| Basic and diluted loss per share | $0.07 | $0.32 (restated) |
| Cash used in operating activities | $630,015 | $858,533 |
Lower research and development and general and administrative expenses drove the reduced loss versus 2016. With no revenue, margins are not meaningful. The audited statements report December 31, 2017 cash of $2,959, total assets of $29,530, current liabilities of $1,011,941, total liabilities of $1,618,106, and stockholders’ deficit of $1,588,576. Management reported negative working capital of $1,003,228.
At year-end, the balance sheet showed $317,635 of current convertible notes and $606,165 of longer-term convertible notes, plus $67,846 of accrued interest. The filing also reports that $1.9 million was raised in the first quarter of 2018 through equity and debt financing; it says further funding will be needed.
Material changes and unusual items
- The 2016 comparative results were restated. The filing cites previously unrecorded fair-value accounting for an option to purchase convertible notes and warrants; the restatement increased 2016 net loss by $336,272.
- A 2017 settlement with noteholders extended certain notes to June 2019 and increased principal amounts. It also provided for Series A convertible preferred stock with a stated value and liquidation preference of $529,000.
- After year-end, certain investors acquired loans totaling $956,209; the filing says $73,000 was converted into 7.3 million shares at $0.01 per share, with a further $9,218 converted into 921,800 shares in March 2018.
- The company entered a binding term sheet for an exclusive distributor in Turkey and Turkish Northern Cyprus. Appointment is subject to a $250,000 fee, of which $150,000 is an advance against future product purchases. The filing does not establish that this fee was paid or that products were ready for commercial deployment.
- The filing reports post-year-end unit sales at $0.07 per unit, each with a common share and a warrant exercisable at $0.14, and states that total first-quarter 2018 fundraising was approximately $1.9 million.
Outlook, risks, and contingencies
The auditor issued an unqualified opinion but included a going-concern explanatory paragraph, citing the company’s lack of revenue and operating losses. Management stated that additional financing is necessary and that there is no assurance it will be available. Management expects no positive operating cash flow for the foreseeable future.
The new cryptocurrency business is at an early stage, with products still in development, no established operating history, and no firm manufacturing arrangements disclosed. Key risks include product development and acceptance, competition, cryptocurrency regulation and adoption, cybersecurity, financing needs, and dilution. The filing reports ineffective disclosure controls and material weaknesses in financial reporting controls, including insufficient accounting personnel; management said corrective action was planned to begin in the second quarter of 2018.
Former employees’ claims of less than $96,000 were included in current liabilities, and a court process sought liquidation of Emerald IL to satisfy its debts. A former CEO separately claimed $100,000 for alleged wrongful dismissal; the company disputed the claim, and no provision was recorded. The company reported no off-balance-sheet arrangements or contractual obligations at December 31, 2017.
Important facts for investors to verify
- Confirm the registrant’s identity and current legal name: the filing identifies Virtual Crypto Technologies, Inc., not Quantum X Labs Inc.
- Reconcile reported figures: the MD&A and financial statements differ on 2017 operating cash use; the filing also contains conflicting comparative liability and debt figures.
- Verify the amount, timing, and terms of first-quarter 2018 financing, including conversions, shares issued, warrants, and remaining cash runway.
- Confirm whether the distributor appointment fee was paid, product development and testing status, manufacturing arrangements, and any resulting sales.
- Assess the Emerald IL liquidation, employee liabilities, and former CEO litigation, and track progress addressing the disclosed control weaknesses.
- Review potential dilution from outstanding warrants, convertible instruments, and the substantially larger share count reported after year-end.